This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"VYCOR Should Enter Hyper-growth During the Next Two to Three Years. Vycor's ViewSite is already making good inroads into the relatively small neurosurgery market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early 2013. However, we are most excited about the long-term potential of the NovaVisionsubsidiary, as its products have no real competition and address a global market that could be up to $20B in size. Although NovaVision's products could require several years to achieve market penetration of even 5%, this would still equate to a huge win for a company of this size. Both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States."
"Since its introduction in 2010, the ViewSite Brain Access System has been used to perform over 3,000 brain surgery procedures, and it has either been approved or is being evaluated by some 130 hospitals in the United States alone."
"NovaVision provides a home-based treatment of vision rehabilitation after stroke or brain injury called Vision Restoration Therapy (VRT™). VRT is an FDA-cleared, patented, non-invasive medical device that enhances visual functions in patients with impairments due to stroke, surgical intervention, and traumatic brain injury (TBI). "
"Stroke and traumatic brain injury (TBI) victims are almost always told by their doctors that vision loss causedby neurological brain damage is permanent and irreversible; these doctors have been taught this "fact" since early in their careers, and they mostly accept it as a fact, without question. However, according to six Company-sponsored studies and fourteen independent studies, conducted over a period of 15 years, this is not a fact at all. It is instead a previously-valid medical conclusion based on old data and technology - it is not based on current research. We believe the new data regarding recently-developed technology (i.e. NovaVision's VRT and NeET) have clearly shown that vision loss can be at least partially restored in most cases..."
Well said. In fact, allowing a moment to breathe is often the sign of a an organic investor movement destined to rise as opposed to a spasmodic pop and drop
The average cost of NovaVision therapy to restore vision loss due to traumatic brain injury is $2100. Compare that to Lasik surgery (which merely improves vision, not restores it like NovaVision) at $500 to $1000 per eye.
You can easily see why the market penetration opportunity is so achievable for VYCO. Who wouldn't spend $2100 to recover their vision?
Just trying to lay the facts on the table. If anyone has any other ideas for the Ibox,let me know.
All in all, nice to end GREEN. Validates that the big spike in volume on Friday was accumulation by long term investors becoming aware of how undervalued VYCO is. Not merely daytraders jumping in for a quick ride.
Slower day here. Awareness is still building.
VYCO in GREEN! Medical technology that restores sight to stroke victims, formally thought impossible
VYCO accumulation play. Organic awareness is growing. 1 MM till .02
VYCO greeeeen!! 1 mm to .02
VYCO thin to .02, stellar organic play in the making. NO PR campaign!
VYCO: Do you know why it got 14x's volume on Friday? Medical technology that literally makes the blind see
VYCO in the green, 1 mm to .02
.019, thin to .02, only one MM
VYCO Patent Details:
Intellectual Property
Patent Applications
Below is a table setting out the status and particulars of our patent applications:
Filing Date
Application No.
Country
Title
Status
June 22, 2005
60/692,959
US — provisional
Surgical Access
Instruments for Use
with Spinal or Orthopedic
Surgery (Cervical)
Converted to PCT
June 22, 2006
PCT/US06/24243
PCT
Surgical Access
Instruments for Use with
Spinal or Orthopedic
Surgery (Cervical)
National Phase Completed
June 22, 2005
11/155,175
US — utility
Surgical Access
Instruments for Use with
Delicate Tissues (Brain)
Final Office Action issued – response with one extension due August 23, 2009
November 27, 2006
PCT/US06/61246
PCT
Surgical Access
Instruments for Use with
Delicate Tissues (Brain)
National Phase Completed
June 22, 2006
2613323
Canada
Surgical Access
Instruments for Use with
Spinal or Orthopedic
Surgery
Pending
June 22, 2006
06785312.7
Europe
Surgical Access
Instruments for Use with
Spinal or Orthopedic
Surgery
Pending
June 22, 2006
299/KOLNP/2008
India
Surgical Access
Instruments for Use with
Spinal or Orthopedic
Surgery
Pending
June 22, 2006
188321
Israel
Surgical Access
Instruments for Use with
Spinal or Orthopedic
Surgery
Pending
June 22, 2006
2008-518369
Japan
Surgical Access
Instruments for Use with
Spinal or Orthopedic
Surgery
Published
December 20, 2007
11/993,280
US – utility
Surgical Access Instruments
Notice of Missing
27
--------------------------------------------------------------------------------
for use with spinal or orthopedic surgery
Requirements – Decl/POA due September 9, 2009
June 25, 2008
08107050.4
Hong Kong
Surgical Access Instruments for use with spinal or orthopedic surgery
Pending
September 18, 2008
61/098041
US – provisional
Surgical Access Instruments for use with Delicate Tissues (Brain)
Convert to utility – foreign file due September 18, 2009
May 25, 2009
Canada
Surgical Access Instruments for use with Delicate Tissues (Brain)
Pending
May 26, 2009
06840022.5
Europe
Surgical Access Instruments for use with Delicate Tissues (Brain)
Voluntary Amendments due August 18, 2009
May 26, 2009
1977/KOLNP/2009
India
Surgical Access Instruments for use with Delicate Tissues (Brain)
Pending
May 27, 2009
Japan
Surgical Access Instruments for use with Delicate Tissues (Brain)
Examination due November 27, 2009
June 26, 2009
2009124446
Russia
Surgical Access Instruments for use with Delicate Tissues (Brain)
Examination due November 27, 2009
July 27, 2009
China
Surgical Access Instruments for use with Delicate Tissues (Brain)
Examination due November 27, 2009
The above-indicated patent applications were invented by Dr. John Mangiardi, who assigned the rights to the Sawmill Trust on September 17, 2005 under the terms of an assignment agreement between the parties. The Sawmill Trust then, in turn, assigned the same rights to us on September 17, 2005 pursuant to an assignment agreement between the Sawmill Trust and the Company dated the same date. The consideration for such assignment was the issuance of one-third of the initial equity of our predecessor (Vycor Medical, LLC) and the inclusion of certain rights in favor or the Sawmill Trust, including but not limited to certain supermajority voting rights and the right to appoint members of the board of managers, which were incorporated in the Operating Agreement of such entity. Dr. Mangiardi’s wife, Pascale Mangiardi, who is a director of the Company, was the Settlor of the Sawmill Trust and Dr and Mrs. Mangiardi are both beneficiaries of the Sawmill Trust. The Sawmill Trust is an irrevocable trust and A. Mitchell Green is the sole Trustee and has sole voting power and investment power with respect to the assets of the trust.
VYCO Investment Gameplan, 3 phases
I'm discerning three phases that the VYCO success story will pass through as it regards investment opportunity:
-Pre Awarness: This is where we at now. We have a ticker that has been lying quiet, not focusing on IR at all, but just on building massively legit product offering past concept and commercialization into actual initial market penetration in a $20B market. Chartist wonder what the fuss is about, and a few lucky newcomers shakily take their stand. Discerning early adopter investors have the greatest potential for massive upside. We saw a big upswell of this kind of accumulation on Friday with 14x's the average volume. Market gurus staking their claim. This is primordial soup of which the ultra rich are born, like buying AAPL before everyone has heard of the Ipod and MP3. Defintion of a ridiculous bargain. Those who join the long team here are staking their claim before the covered wagons have even started rolling.
-Organic Awareness ground swell. Coming in the very near future. The cream will rise to the top and you can't keep a good man down. As the core long team finds its footing, company begins to find traction in awareness. Still a massive bargain like AAPL pre I-phone. Volume begins to show signs of true potential. Longs who were already in begin to look like old time market gurus and newly minted longs spread the word by every means possible. Buyin becomes more competitive and some even begin to take a taste of profit as a reward of their foresight. This is the time when orchestrated IR is like the the first arresting notes your soul craves in a symphony promising beautiful crescendos. Chartists are all abuzz. Long team has grown past a very prescient group of market early adopter gurus to a whole network of respected market mavens with reputation for getting in when the getting is good. Increasingly consistent volume and the normal shakeouts as the ticker rises provides multiple points of entry and exit.
-Mature Market success story, mainstream attention and whole series of increasing successful IR campaigns brings in the consistent volume and PPS jumps that makes the chart look like the hills rising from the plains to the, foothils, to one dizzying peak in the clouds to the next. Ipad anyone? General public now cannot ignore whats happening and the average Joe investor is asking self: why do I always hear about this stuff after the millionaires are made? Institutionals are actively trading. Deserved volume becomes a staple of options traders and the conservative longs begin their strategy of buying in the dips and adding to retirement portfolios. Early adopter gurus take profits to buy their yachts and summer homes, Mavens to buy wife a new car.
Bottom line: This is the time to get in. If you shoot at some food and bubbling crude comes up, sell the jalopey and buy the back 40 before Exxon comes knocking. Beverly hills is a'waiting.
Message me to chat and strategize more, teammates! Victory comes as we pull together.
Harbinger Analysis on VYCO: Strong Buy. The info below is from the introduction. The whole report can be found here:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
Vycor Medical Inc. (VYCO.OB - OTCBB)
Vycor Medical Has Breakthrough Product Offerings in the
Neurosurgical and Stroke-Related Vision Rehabilitation
Markets. We Expect Strong Sales Growth in Late 2012 and
2013, and See Sustainable Hyper-growth Potential in 2014
and Beyond.
• $1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.
• ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes
The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage
caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also
provides these surgeons with superior visibility during surgical procedures. The net effect of
this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases
this product's superior attributes have allowed brain surgeons to successfully perform surgeries
that would have otherwise been considered inoperable. The VBAS is protected by a strong
patent portfolio, and we believe its clinical superiority and cost savings will lead it to become
the de facto standard in surgical devices for neurosurgery over the next few years.
• The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
• We Believe an Investment in Vycor is Somewhat Risky but Has Exceptional Potential
Based on solid near-term growth prospects and extreme upside in potential in 2013 and
beyond, we are initiating coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share. Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
foresee.
I agree, such an amazing product offering here. When you have stroke survivors who were told by doctors that their vision loss was permanent, and then after treatment by VYCO's technology, they actually regain their vision... Well it's not hard to figure out why VYCO is building a groundswell of organic, long term, investor confidence.
"70% of my patients respond to this therapy... enhanced mobility, avoidance of obstacles, improved vision."
Wow, amazing to see a stroke survivor with vision loss go on to pass a drivers license exam after VYCO Novavision therapy.
VYCO definitely shows the signs of a strong, long, organic play in the making. The thing to remember is that this is still the premarket awareness phase. Fridays accumulation is very telling.
I'd like to see the same accumulation trend continue. When you see that kind of accumulation without a promo going on, its a good sign that organic awareness is reaching a tipping point. IN THE KNOW high rollers can smell a winner entering the gate.
The accumulation we saw on Friday was a sign of good things to come. Lots of saavy heavy hitter are staking positions with VYCO in light of excellent fundamentals. Those who have a strong instinct for big plays forming are quitely marking out territory with VYCO.
Welcome Jack_Bauer!
If anyone has any ideas for the IBOX please let me know. Little hard to digest the way it is. All the recent activity should have unaware traders asking why all the interest? I would like the IBOX to help answer that some...
Hopefully going to work on the IBOX this weekend. Does quite do the VYCO story justice at the moment.
VYCO: 13Xs avg Vol, 77% gain, true organic long play just revving up. FDA approved technology, treated 2,000 patients ACTUALLY restores sight to stroke victims!! The DD will make you bark:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO True organic long play just revving up. FDA approved technology, treated 2,000 patients ACTUALLY restores sight to stroke victims!! The DD will give you an arrythmia:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO is now #2 on IHUB breakout boards: ORGANIC PLAY!
VYCO: Hottest Stock you never heard of !13Xs avg Vol, 77% gain, true organic long play just revving up. FDA approved technology, treated 2,000 patients ACTUALLY restores sight to stroke victims!! The DD will make you gasp:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO Summary and Investment Opportunity
• $1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.
• ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes
The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage
caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also
provides these surgeons with superior visibility during surgical procedures. The net effect of
this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases
this product's superior attributes have allowed brain surgeons to successfully perform surgeries
that would have otherwise been considered inoperable. The VBAS is protected by a strong
patent portfolio, and we believe its clinical superiority and cost savings will lead it to become
the de facto standard in surgical devices for neurosurgery over the next few years.
• The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
• We Believe an Investment in Vycor is Somewhat Risky but Has Exceptional Potential
Based on solid near-term growth prospects and extreme upside in potential in 2013 and
beyond, we are initiating coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share. Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
Harbinger analysis hinted at a possible 15x gain, longs could attain it here IMHO
VYCO 5ALARMFIRE!Now-13Xs avg Vol, 77% gain, true organic long play just revving up. The DD will make you sigh:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO: Keep hitting that ASK! 13Xs avg Vol, 77% gain, true organic long play just revving up. The DD will knock your socks off:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO: Keep hitting that ASK! 13Xs avg Vol, 77% gain, true organic long play just revving up. The DD will knock your socks off:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
Longs need to keep their nose buried in the DD, there will be reversals along the way, there always are, but if those who know what they're holding keep pushing together the gains here will be staggering
VYCO:
-200% revenue increase
-Patent protected, 20!
-technology restores sight and makes impossible brain surgeries possible
-$20B sector
-already in 1200 hospitals, FDA Approved
Nothing but grassroots awareness and already half way to 5 bagger that the Harbinger report pegged. Looks like the 15x gain they speculated could be in reach.
Longs need to hold the line, shoulder to knee, and press the advantage